- Home
- RDUS vs EXEL Comparison
RDUS vs EXEL Comparison
Compare RDUS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDUS
- EXEL
- Stock Information
- Founded
- RDUS 1906
- EXEL 1994
- Country
- RDUS United States
- EXEL United States
- Employees
- RDUS N/A
- EXEL N/A
- Industry
- RDUS Industrial Specialties
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDUS Consumer Discretionary
- EXEL Health Care
- Exchange
- RDUS Nasdaq
- EXEL Nasdaq
- Market Cap
- RDUS N/A
- EXEL 9.8B
- IPO Year
- RDUS 1993
- EXEL 2000
- Fundamental
- Price
- RDUS $29.24
- EXEL $37.43
- Analyst Decision
- RDUS Hold
- EXEL Buy
- Analyst Count
- RDUS 2
- EXEL 18
- Target Price
- RDUS $22.00
- EXEL $37.59
- AVG Volume (30 Days)
- RDUS 1.2M
- EXEL 2.4M
- Earning Date
- RDUS 04-04-2025
- EXEL 05-02-2025
- Dividend Yield
- RDUS 2.56%
- EXEL N/A
- EPS Growth
- RDUS N/A
- EXEL 170.77
- EPS
- RDUS N/A
- EXEL 1.76
- Revenue
- RDUS $2,743,781,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- RDUS $2.35
- EXEL $5.82
- Revenue Next Year
- RDUS $7.03
- EXEL $10.81
- P/E Ratio
- RDUS N/A
- EXEL $21.27
- Revenue Growth
- RDUS N/A
- EXEL 18.50
- 52 Week Low
- RDUS $10.57
- EXEL $20.14
- 52 Week High
- RDUS $29.29
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- RDUS 77.95
- EXEL 57.87
- Support Level
- RDUS $28.81
- EXEL $35.34
- Resistance Level
- RDUS $29.25
- EXEL $37.67
- Average True Range (ATR)
- RDUS 0.37
- EXEL 1.32
- MACD
- RDUS -0.48
- EXEL 0.22
- Stochastic Oscillator
- RDUS 96.03
- EXEL 95.46
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.